Case Serieslow evidence
Human embryonic stem cell-derived dopaminergic cells for Parkinson's disease: a phase 1/2 open-label trial.
Nature medicine·July 9, 2026·PMID 42426223
Why it mattersThis early-phase trial provides initial human safety data for a restorative cell therapy targeting the underlying dopaminergic deficit in Parkinson's disease, addressing a critical unmet need for disease-modifying interventions.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled